Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Astrazeneca Plc (NY: AZN)
48.56 USD  +0.64 (+1.34%)
Streaming Delayed Price  /  Updated: 4:55 AM EST, Dec 13, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,931
Open 47.92
Bid (Size) 48.49 (8)
Ask (Size) 48.53 (4)
Prev. Close 47.92
Today's Range 47.92 - 48.86
52wk Range 35.30 - 49.22
Shares Outstanding 2,533,294,824
Dividend Yield 2.82%
Performance
YTD
+28.47%
+28.47%
1 Month
+3.14%
+3.14%
3 Month
+13.19%
+13.19%
6 Month
+21.67%
+21.67%
1 Year
+24.80%
+24.80%
Top News
More News
[Fam]-Trastuzumab Deruxtecan Achieved a Tumor Response of 60.9% in Pivotal Phase II HER2-positive Metastatic Breast Cancer Trial
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of [fam]-trastuzumab... Read More
from Business Wire News Releases
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that CALQUENCE® (acalabrutinib) combined with obinutuzumab or as monotherapy significantly... Read More
from Business Wire News Releases
More News
Read More
AstraZeneca May Have Knocked One Out of the Park
category DSNKY , RHHBY , AZN , and 1 more.
from Motley Fool
Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
category Stocks / Equities , Pharma/Biotech
from Blogs - TalkMarkets
Week in Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
from ChinaBio® Today
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
from ChinaBio® Today
REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
category companyNews
from Reuters: Company News
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
from ChinaBio® Today
AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
category companyNews
from Reuters: Company News
China to use drug bulk-buy program to close price gap
category companyNews
from Reuters: Company News
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street
category TECD , Futures , US Stock Futures , and 11 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.